COHERUS BIOSCIENCES, INC — Lobbying Disclosure | Poliscope

COHERUS BIOSCIENCES, INC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$4.6M

Filings

Firms Hired

Active Period

2015–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$175,000	5	2
2025	$475,000	9	2
2024	$315,000	11	3
2023	$1,000,000	16	4
2022	$975,000	16	4
2021	$490,000	12	3
2020	$125,000	8	2
2017	$440,000	4	1
2016	$480,000	4	1
2015	$160,000	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
COHERUS BIOSCIENCES, INC	$4,635,000	38
INLET STRATEGIES	—	19
CAPITOL HILL CONSULTING GROUP	—	17
ALSTON & BIRD LLP	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	82
HOUSE OF REPRESENTATIVES	73
Health & Human Services, Dept of (HHS)	51
White House Office	41
Natl Security Council (NSC)	35
Office of Management & Budget (OMB)	29
Centers For Medicare and Medicaid Services (CMS)	27
Executive Office of the President (EOP)	24
Defense, Dept of (DOD)	20
Office of Science & Technology Policy (OSTP)	20
Food & Drug Administration (FDA)	17
Homeland Security, Dept of (DHS)	16
Commerce, Dept of (DOC)	12
Energy, Dept of	10
Vice President of the U.S.	10
Defense Advanced Research Projects Agency (DARPA)	7
Defense Nuclear Facilities Safety Board	7
Federal Emergency Management Agency (FEMA)	7
President of the U.S.	7
Congressional Budget Office (CBO)	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	82
Medicare/Medicaid	Medicare/Medicaid	59
Government Issues	Government Issues	27
Budget/Appropriations	Budget/Appropriations	9
Pharmacy	Pharmacy	9
Copyright/Patent/Trademark	Copyright/Patent/Trademark	9
Veterans	Veterans	1
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · fourth_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $65,000 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2024 · fourth_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $65,000 · Firm income: —

Matched citations: S.3311

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · fourth_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D Issues related to the strategic national stockpile Issues related to the procurement of the medicine "Udenyca" for the treatment of acute radiation exposure

Client expense: — · Firm income: $45,000

Matched citations: S.1339

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · fourth_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of biosimilars within Medicare Part D Issues related to the strategic national stockpile Issues related to the procurement of the medicine "Udenyca" for the treatment of acute radiation exposure

Client expense: — · Firm income: $45,000

Matched citations: S. 1339

Show 21 more cited filings

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · third_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 1339

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · third_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S.1339

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · third_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $45,000 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2024 · third_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $45,000 · Firm income: —

Matched citations: S.3311

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · second_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $87,500 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2024 · second_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $87,500 · Firm income: —

Matched citations: S.3311

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · second_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to FDA Inspections Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 1339

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · second_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to FDA Inspections Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S.1339

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · second_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $30,000 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2024 · second_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $30,000 · Firm income: —

Matched citations: S.3311

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · first_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $87,500 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2024 · first_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $87,500 · Firm income: —

Matched citations: S.3311

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · first_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S.1339

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · first_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 1339

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · first_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 2082

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2024 · first_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 2082

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2023 · fourth_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $175,000 · Firm income: —

Matched citations: S.2082

S. 3311118th Congress

American Made Pharmaceuticals Act of 2023

2023 · fourth_quarter · Firm: COHERUS BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Client expense: $175,000 · Firm income: —

Matched citations: S.3311

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2023 · fourth_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 1339

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2023 · fourth_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to drug shortages and the pharmaceutical supply chain S.1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S.1339

S. 2082118th Congress

Ensuring Justice for Victims of Terrorism Act

2023 · fourth_quarter · Firm: INLET STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

S. 2082 The American Made Pharmaceuticals Act Drug Pricing Reform Issues related to FDA Inspections Issues related to reform of pharmacy benefit managers Issues related to drug shortages and the pharmaceutical supply chainS. S. 1339 The Pharmacy Benefit Manger Reform Act Issues related to coverage of Biosimilars within Medicare Part D

Client expense: — · Firm income: $45,000

Matched citations: S. 2082

Source: Senate LDA